| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 11
| Issue : 3 | Page : 90-99 |
|
|
Current medicines for malaria including resistance issues
Dejen Nureye1, Mohammed Salahaddin2, Ameha Zewudie1
1 Department of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Aman Campus, Mizan-Aman, Ethiopia
2 Department of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Aman Campus, Mizan-Aman, Ethiopia; Department of Biomolecular Sciences, Pharmacology Division, University of Mississippi, Mississippi, United States of America
Correspondence Address:
Dejen Nureye
Department of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Aman Campus, P.O. Box 260, Southwest, Mizan-Aman
Ethiopia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jpp.JPP_23_20
|
|
|
Malaria is an old disease and continues to be a major health problem in many countries. In spite of decrement in morbidity and mortality due to malaria, the transmission is still active throughout the world. Hence, appropriate treatment is needed to handle malaria in addition to preventive measures. However, unavailability of new drugs and the occurrence of resistant Plasmodium strains toward many conventional antimalarial drugs including artemisinins are the major obstacles in combating malaria infection. Thus, experts from all directions of our planet are in search of novel compounds, and many new chemical entities, such as artefenomel, ferroquine, KAE609, KAF156, DSM265, methylene blue, MMV39048, DDD107498, SJ733, and MMV253, have been under drug development process. While many agents are in the pipeline, most of them are not able to kill both gametocytes and hypnozoites.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
